Abstract
The androgen receptor inhibitors (ARI) enzalutamide, apalutamide, and darolutamide have been recommended for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). With the publication of the final analysis of the overall survival of the patients in the three main randomized controlled trials that evaluated these drugs, a systematic analysis of their benefits and risks is once again necessary. The aim of this study is to conduct a meta-analysis of the efficacy and safety of ARIs for the treatment of nmCRPC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
